Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy
Mohammed Fatih Rasul, Bashdar Mahmud Hussen, Abbas Salihi, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges
Bashdar Mahmud Hussen, Mohammed Fatih Rasul, Snur Rasool Abdullah, et al.
Military Medical Research (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 59
Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies
Xuan‐Thanh‐An Nguyen, Lude Moekotte, Astrid S. Plomp, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7481-7481
Open Access | Times Cited: 57
Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery
Alaa A. A. Aljabali, Mohamed El‐Tanani, Murtaza M. Tambuwala
Journal of Drug Delivery Science and Technology (2024) Vol. 92, pp. 105338-105338
Open Access | Times Cited: 45
Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing
Misganaw Asmamaw Mengstie, Muluken Teshome Azezew, Tadesse Asmamaw Dejenie, et al.
Biologics (2024) Vol. Volume 18, pp. 21-28
Open Access | Times Cited: 27
Microbiome-Driven Therapeutics: From Gut Health to Precision Medicine
Muneer Yaqub, Aashika Jain, Chinedu Eucharia Joseph, et al.
Gastrointestinal Disorders (2025) Vol. 7, Iss. 1, pp. 7-7
Open Access | Times Cited: 6
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
Wei Wei, Zhi‐Nan Chen, Ke Wang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12317-12317
Open Access | Times Cited: 41
CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective
Deepak Kumar Sahel, Lalitkumar K. Vora, Aishwarya Saraswat, et al.
Advanced Science (2023) Vol. 10, Iss. 19
Open Access | Times Cited: 36
Evolution of CRISPR/Cas Systems for Precise Genome Editing
Magdalena Hryhorowicz, Daniel Lipiński, Joanna Zeyland
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14233-14233
Open Access | Times Cited: 27
An Update on the Application of CRISPR Technology in Clinical Practice
Firouzeh Morshedzadeh, Mahmoud Ghanei, Malihe Lotfi, et al.
Molecular Biotechnology (2023) Vol. 66, Iss. 2, pp. 179-197
Open Access | Times Cited: 25
Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches within Tumor Cells: A Future Perspective of Cancer Management
Khaled S. Allemailem, Saleh A. Almatroodi, Ahmad Almatroudi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7052-7052
Open Access | Times Cited: 23
Optimizing CRISPR/Cas9 precision: Mitigating off-target effects for safe integration with photodynamic and stem cell therapies in cancer treatment
J. P. Jose Merlin, Heidi Abrahamse
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117516-117516
Open Access | Times Cited: 13
Molecular insights into regulatory RNAs in the cellular machinery
Sumin Yang, Sung-Hyun Kim, Eun-Jeong Yang, et al.
Experimental & Molecular Medicine (2024) Vol. 56, Iss. 6, pp. 1235-1249
Open Access | Times Cited: 12
Systemic and Local Strategies for Primary Prevention of Breast Cancer
Erin K. Zaluzec, Lorenzo F. Sempere
Cancers (2024) Vol. 16, Iss. 2, pp. 248-248
Open Access | Times Cited: 11
Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways
Mohammad Yasin Zamanian, Maryam Golmohammadi, Alexey Yumashev, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 4
Open Access | Times Cited: 9
Landscape of exosomes to modified exosomes: a state of the art in cancer therapy
Divya Mirgh, Swarup Sonar, Srestha Ghosh, et al.
RSC Advances (2024) Vol. 14, Iss. 42, pp. 30807-30829
Open Access | Times Cited: 9
Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication
Ana Borrajo
Life (2025) Vol. 15, Iss. 2, pp. 276-276
Open Access | Times Cited: 1
Reinvigorating AMR resilience: leveraging CRISPR–Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security—a systematic review
Olalekan John Okesanya, Mohamed Mustaf Ahmed, Jerico Bautista Ogaya, et al.
Tropical Medicine and Health (2025) Vol. 53, Iss. 1
Open Access | Times Cited: 1
Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy
Ankit Kumar Dubey, Ebrahim Mostafavi
Frontiers in Chemistry (2023) Vol. 11
Open Access | Times Cited: 21
Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics
Vinayak Nayak, Sushmita Patra, Kshitij RB Singh, et al.
Environmental Research (2023) Vol. 235, pp. 116573-116573
Closed Access | Times Cited: 20
Oncolytic viral therapy for gliomas: Advances in the mechanisms and approaches to delivery
Alexander Romanishin, A. Yu. Vasil’ev, E Khasanshin, et al.
Virology (2024) Vol. 593, pp. 110033-110033
Open Access | Times Cited: 8
Huntington’s Disease Drug Development: A Phase 3 Pipeline Analysis
Hannah J. Van de Roovaart, Nguyen Nguyen, Timothy D. Veenstra
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1513-1513
Open Access | Times Cited: 15
The promise of CRISPR/Cas9 technology in diabetes mellitus therapy: How gene editing is revolutionizing diabetes research and treatment
Yan Cheng, Haiyang Wang, Mo Li
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 8, pp. 108524-108524
Closed Access | Times Cited: 14
CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy
Valentine De Castro, Jeanne Galaine, Romain Loyon, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 8, pp. 1124-1134
Closed Access | Times Cited: 6
Engineering CRISPR/Cas9 therapeutics for cancer precision medicine
Aditya Sharma, Anil K. Giri
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 6
Crispr-Cas based biosensing: A fast-expanding molecular diagnostic tool
Shweta Singh, Rinku Thakran, Ankur Kaushal, et al.
Microchemical Journal (2024) Vol. 200, pp. 110421-110421
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top